Innovative Drug Enhances Immune Attack on Liver Cancer by Targeting Fat Metabolism
A groundbreaking drug developed at McMaster University shows promise in fighting liver cancer by blocking fat metabolism and activating the immune system, particularly B cells, offering new hope for treatment-resistant cases.
Researchers at McMaster University, in collaboration with Espervita Therapeutics, have developed a promising new treatment aimed at combating liver cancer, particularly in patients with fatty liver disease. Liver cancer cells are known to rely heavily on fat metabolism for their growth and survival, contributing to poor prognosis for millions worldwide. The new therapy centers around inhibiting an enzyme called ATP citrate lyase (ACLY), which plays a crucial role in converting sugars into fats within the tumor environment.
The drug, designated EVT0185, selectively targets ACLY in the liver. When tested in mice models afflicted with metabolic dysfunction and liver cancer, EVT0185 effectively reduced tumor size and made cancer cells more susceptible to immune system attack. Surprisingly, the enhanced immune response was driven not by the well-understood T cells but by B cells, a type of immune cell less commonly associated with tumor destruction.
This groundbreaking study, published in Nature, reveals a novel approach to cancer immunotherapy by modulating tumor metabolism. The findings suggest that blocking metabolic pathways in tumors can potentiate the body's natural defenses, opening avenues for more effective treatments, especially for cases resistant to conventional therapies.
Liver cancer, often linked to metabolic conditions like fatty liver disease (MASLD) and its severe form MASH, remains a significant health challenge. Currently, survival rates are dismally low, with fewer than 20% of patients living beyond five years. The ability of EVT0185 to inhibit tumor growth and activate B cell-mediated immunity offers hope for new therapeutic strategies.
While these results are promising, further research is required to understand how ACLY inhibition enhances immune responses and whether similar effects can be observed in humans and other cancer types. This innovative approach marks a significant step toward tailored treatments that target the metabolic vulnerabilities of tumors and harness the immune system more effectively.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
AI Technology Enables Early Detection of Surgical Site Infections via Patient Photos
Mayo Clinic researchers have developed an AI system that accurately detects surgical site infections from patient-submitted photos, promising faster and more efficient postoperative care. This innovative technology could transform wound monitoring and early infection detection.
Affordable HIV Medication Shows Promise in Improving Vision for Diabetic Macular Edema Patients
A cost-effective HIV drug, lamivudine, shows promising results in improving vision for diabetic macular edema patients, offering a convenient and affordable alternative to traditional therapies in clinical trials.
Innovative Gene Therapy Offers New Hope for Alagille Syndrome Patients
A novel gene therapy approach shows promise in treating Alagille syndrome, potentially reducing the need for liver transplants and reversing liver damage in affected patients.
Cerebellar Stimulation Shows Potential to Improve Reward Processing in Healthy Adults
A groundbreaking study explores how cerebellar neuromodulation via HD-tDCS can enhance reward processing and motivation in healthy adults, opening new possibilities for psychiatric treatments.